Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Templeton Growth Fund PA (0P0001L44H)

Other OTC - Other OTC Delayed Price. Currency in USD
7.50+0.06 (+0.76%)
At close: 03:00PM EST
Advertisement
Full screen
Previous Close7.44
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • GlobeNewswire

    Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

    Full Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New ClientsSAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophil

  • GlobeNewswire

    Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

    Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market

Advertisement
Advertisement